Connexin 43 is required for the anti-apoptotic effect of bisphosphonates on osteocytes and osteoblasts in vivo

Journal of Bone and Mineral Research

Volumn 23, Issue 11, 2008, Pages 1712-1721

  Plotkin, Lilian I ^a,b   Lezcano, Virginia ^c   Thostenson, Jeff ^d   Weinstein, Robert S ^a   Manolagas, Stavros C ^a   Bellido, Teresita ^a,b  

^a CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSIDAD NACIONAL DEL SUR   (Argentina)

^d UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Apoptosis; Bisphosphonates; Connexin43; Osteoblasts; Osteocytes

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CONNEXIN 43; GLUCOCORTICOID; MESSENGER RNA; PREDNISOLONE;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BONE DENSITY; BONE MASS; BONE MINERALIZATION; CELL AGING; CELL DEGENERATION; CELL KINETICS; CELL PROTECTION; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; EXPERIMENTAL MOUSE; FEMALE; GENE DELETION; GENE EXPRESSION; GROWTH INHIBITION; IN VIVO STUDY; MOUSE; NEWBORN; NONHUMAN; OSTEOBLAST; OSTEOCYTE; OSTEOLYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ALENDRONATE; ANIMALS; APOPTOSIS; BONE DENSITY; BONE RESORPTION; CELL DIFFERENTIATION; CELLS, CULTURED; CONNEXIN 43; DEXAMETHASONE; DIPHOSPHONATES; FEMALE; GENE DELETION; GENE SILENCING; GENOTYPE; HUMANS; INTEGRASES; MICE; OSTEOBLASTS; OSTEOCALCIN; OSTEOCYTES; PHENOTYPE; PROMOTER REGIONS, GENETIC; WEIGHT GAIN;

EID: 54249141694     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.080617     Document Type: Article

References (50)

1. Batch JA, Couper JJ, Rodda C, Cowell CT, Zacharin M 2003 Use of bisphosphonate therapy for osteoporosis in childhood and adolescence. J Paediatr Child Health 39:88-92.
2. Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, Black DM 2002 Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 112:281-289.
3. Falk MJ, Heeger S, Lynch KA, DeCaro KR, Bohach D, Gibson KS, Warman ML 2003 Intravenous bisphosphonate therapy in children with osteogenesis imperfecta. Pediatrics 111:573-578.
4. Reid IR, King AR, Alexander CJ, Ibbertson HK 1988 Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1- bisphosphonate (APD). Lancet 1:143-146.
5. Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Delmas PD, Malice MP, Czachur M, Daifotis AG 1998 Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 339:292-299.
6. Fleisch H 1997 Bisphosphonates in Bone Disease. From the Laboratory to the Patient, 3rd ed. The Partenon Publishing Group, New York, NY, USA.
7. Papapoulos S 1996 Bisphosphonates. Pharmacology and use in the treatment of osteoporosis. In: Marcus R, Feldman D, Kelsey J (eds.) Osteoporosis. Academic Press, San Diego, CA, USA, pp. 1209-1234.
8. Rodan GA, Fleisch HA 1996 Bisphosphonates: Mechanisms of action. J Clin Invest 97:2692-2696.
9. Azria M, Avioli LV 1996 Calcitonin. In: Bilezikian JP, Raisz LG, Rodan GA (eds.) Principles of Bone Biology, 1st ed. Academic Press, San Diego, CA, USA, pp. 1083-1097.
10. Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, Mundy GR, Boyce BF 1995 Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 10:1478-1487.
11. Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T 1999 Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 104:1363-1374.
12. Kogianni G, Mann V, Ebetino F, Nuttall M, Nijweide P, Simpson H, Noble B 2004 Fas/CD95 is associated with glucocorticoid-induced osteocyte apoptosis. Life Sci 75:2879-2895.
13. Follet H, Li J, Phipps RJ, Hui S, Condon K, Burr DB 2007 Risedronate and alendronate suppress osteocyte apoptosis following cyclic fatigue loading. Bone 40:1172-1177.
14. Plotkin LI, Manolagas SC, Bellido T 2002 Transduction of cell survival signals by connexin-43 hemichannels. J Biol Chem 277:8648-8657.
15. Plotkin LI, Manolagas SC, Bellido T 2006 Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts/osteocytes with novel analogs. Bone 39:443-452.
16. Reaume AG, de Sousa PA, Kulkarni S, Langille BL, Zhu D, Davies TC, Juneja SC, Kidder GM, Rossant J 1995 Cardiac malformation in neonatal mice lacking connexin43. Science 267:1831-1834.
17. Lakso M, Sauer B, Mosinger B Jr, Lee EJ, Manning RW, Yu SH, Mulder KL, Westphal H 1992 Targeted oncogene activation by site-specific recombination in transgenic mice. Proc Natl Acad Sci USA 89:6232-6236.
18. Orban PC, Chui D, Marth JD 1992 Tissue- and site-specific DNA recombination in transgenic mice. Proc Natl Acad Sci USA 89:6861-6865.
19. Zhang M, Xuan S, Bouxsein ML, Von Stechow D, Akeno N, Faugere MC, Malluche H, Zhao G, Rosen CJ, Efstratiadis A, Clemens TL 2002 Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization. J Biol Chem 277:44005-44012.
20. Theis M, de Wit C, Schlaeger TM, Eckardt D, Kruger O, Doring B, Risau W, Deutsch U, Pohl U, Willecke K 2001 Endothelium-specific replacement of the connexin43 coding region by a lacZ reporter gene. Genesis 29:1-13.
21. Silverstein DM, Urban M, Gao Y, Mattoo TK, Spray DC, Rozental R 2001 Renal morphology in connexin43 knockout mice. Pediatr Nephrol 16:467-471.
22. Tozum TF, Oppenlander ME, Koh-Paige AJ, Robins DM, McCauley LK 2004 Effects of sex steroid receptor specificity in the regulation of skeletal metabolism. Calcif Tissue Int 75:60-70.
23. Bellido T, Ali AA, Gubrij I, Plotkin LI, Fu Q, O'Brien CA, Manolagas SC, Jilka RL 2005 Chronic elevation of PTH in mice reduces expression of sclerostin by osteocytes: A novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 146:4577-4583.
24. Bellido T, Ali AA, Plotkin LI, Fu Q, Gubrij I, Roberson PK, Weinstein RS, O'Brien CA, Manolagas SC, Jilka RL 2003 Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism. J Biol Chem 278:50259-50272.
25. Stewart SA, Dykxhoorn DM, Palliser D, Mizuno H, Yu EY, An DS, Sabatini DM, Chen IS, Hahn WC, Sharp PA, Weinberg RA, Novina CD 2003 Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA 9:493-501.
26. Plotkin LI, Manolagas SC, Bellido T 2007 Glucocorticoids induce osteocyte apoptosis by blocking focal adhesion kinase-mediated survival: Evidence for inside-out signaling leading to anoikis. J Biol Chem 282:24120-24130.
27. O'Brien CA, Jia D, Plotkin LI, Bellido T, Powers CC, Stewart SA, Manolagas SC, Weinstein RS 2004 Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology 145:1835-1841.
28. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC 1998 Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids: Potential mechanisms of their deleterious effects on bone. J Clin Invest 102:274-282.
29. Galli C, Zella LA, Fretz JA, Fu Q, Pike JW, Weinstein RS, Manolagas SC, O'Brien CA 2007 Targeted deletion of a distant transcriptional enhancer of the RANKL gene reduces bone remodeling and increases bone mass. Endocrinology 149:146-153.
30. Weinstein RS, Jia D, Powers CC, Stewart SA, Jilka RL, Parfitt AM, Manolagas SC 2004 The skeletal effects of glucocorticoid excess override those of orchidectomy in mice. Endocrinology 145:1980-1987.
31. Jilka RL, Weinstein RS, Parfitt AM, Manolagas SC 2007 Quantifying osteoblast and osteocyte apoptosis: Challenges and rewards. J Bone Miner Res 22:1492-1501.
32. Manolagas SC 2000 Birth and death of bone cells: Basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 21:115-137.
33. Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC 1999 Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 104:439-446.
34. Almeida M, Han L, Bellido T, Manolagas SC, Kousteni S 2005 Wnt proteins prevent apoptosis of both uncommitted osteoblast progenitors and differentiated osteoblasts by beta-catenin-dependent and -independent signaling cascades involving Src/ERK and phosphatidylinositol 3-kinase/AKT. J Biol Chem 280:41342-4351.
35. Bodine PV, Billiard J, Moran RA, Ponce-de-Leon H, McLarney S, Mangine A, Scrimo MJ, Bhat RA, Stauffer B, Green J, Stein GS, Lian JB, Komm BS 2005 The Wnt antagonist secreted frizzled-related protein-1 controls osteoblast and osteocyte apoptosis. J Cell Biochem 96:1212-1230.
36. Aguirre JI, Plotkin LI, Gortazar AR, O'Brien CA, Manolagas SC, Bellido T 2007 A novel ligand-independent function of the estrogen receptor is essential for osteocyte and osteoblast mechanotransduction. J Biol Chem 282:25501-25508.
37. Plotkin LI, Mathov I, Aguirre JI, Parfitt AM, Manolagas SC, Bellido T 2005 Mechanical stimulation prevents osteocyte apoptosis: Requirement of integrins, Src kinases and ERKs. Am J Physiol Cell Physiol 289:C633-C643.
38. Kousteni S, Bellido T, Plotkin LI, O'Brien CA, Bodenner DL, Han L, Han K, DiGregorio GB, Katzenellenbogen JA. Katzenellenbogen BS, Roberson PK, Weinstein RS, Jilka RL, Manolagas SC 2001 Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: Dissociation from transcriptional activity. Cell 104:719-730.
39. Kousteni S, Chen JR, Bellido T, Han L, Ali AA, O'Brien CA, Plotkin L, Fu Q, Mancino AT, Wen Y, Vertino AM, Powers CC, Stewart SA, Ebert R, Parfitt AM, Weinstein RS, Jilka RL, Manolagas SC 2002 Reversal of bone loss in mice by nongenotropic signaling of sex steroids. Science 298:843-846.
40. Weinstein RS, Nicholas RW, Manolagas SC 2000 Apoptosis of osteocytes in glucocorticoid-induced osteonecrosis of the hip. J Clin Endocrinol Metab 85:2907-2912.
41. Jia D, O'Brien CA, Stewart SA, Manolagas SC, Weinstein RS 2006 Glucocorticoids act directly on osteoclasts to increase their lifespan and reduce bone density. Endocrinology 147:5592-5599.
42. Plotkin LI, Goellner J, Vyas K, Shelton R, Wynne R, Weinstein RS, Manolagas SC, Bellido T 2007 A bisphosphonate analog that lacks anti-remodeling activity prevents osteocyte and osteoblast apoptosis in vivo. J Bone Miner Res 22:S4.
43. Lecanda F, Warlow PM, Sheikh S, Furlan F, Steinberg TH, Civitelli R 2000 Connexin43 deficiency causes delayed ossification, craniofacial abnormalities, and osteoblast dysfunction. J Cell Biol 151:931-944.
44. Chung D, Castro CH, Watkins M, Stains JP, Chung MY, Szejnfeld VL, Willecke K, Theis M, Civitelli R 2006 Low peak bone mass and attenuated anabolic response to parathyroid hormone in mice with an osteoblast-specific deletion of connexin43. J Cell Sci 119:4187-4198.
45. Schiller PC, D'Ippolito G, Balkan W, Roos BA, Howard GA 2001 Gap-junctional communication is required for the maturation process of osteoblastic cells in culture. Bone 28:362-369.
46. Donahue HJ, Li Z, Zhou Z, Yellowley CE 2000 Differentiation of human fetal osteoblastic cells and gap junctional intercellular communication. Am J Physiol Cell Physiol 278:C315-C322.
47. Lecanda F, Towler DA, Ziambaras K, Cheng SL, Koval M, Steinberg TH, Civitelli R 1998 Gap junctional communication modulates gene expression in osteoblastic cells. Mol Biol Cell 9:2249-2258.
48. Dobrowolski R, Sasse P, Schrickel JW, Watkins M, Kim JS, Rackauskas M, Troatz C, Ghanem A, Tiemann K, Degen J, Bukauskas FF, Civitelli R, Lewalter T, Fleischmann BK, Willecke K 2008 The conditional connexin43G138R mouse mutant represents a new model of hereditary oculodentodigital dysplasia in humans. Hum Mol Genet 17:539-554.
49. Watkins M, Ornitz D, Willecke K, Civitelli R 2006 Connexin43 is required for normal skeletal development and bone mass acquisition. J Bone Miner Res 21:S56.
50. Zhang Y, Taylor AF, Paul EM, Davison A, Bronson SK, Donahue HJ 2007 Inadequate bone adaptation in bone cell specific connexin43 deficient mice. J Bone Miner Res 22:S80.